Upstream Bio
UPB · Nasdaq · United States
Share price · UPB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when UPB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Nov 2026-22.7%
Nothing announced by UPB that day or the session before.
- 29 Oct 2026+9.7%
Nothing announced by UPB that day or the session before.
- 22 Oct 2026+6.8%
Nothing announced by UPB that day or the session before.
- 16 Oct 2026-18.1%
Nothing announced by UPB that day or the session before.
- 13 Oct 2026-14.9%
Nothing announced by UPB that day or the session before.
- 12 Oct 2026-11.3%
Nothing announced by UPB that day or the session before.
- 3 Sep 2026-6.2%
Nothing announced by UPB that day or the session before.
- 1 Jul 2026+5.2%
Nothing announced by UPB that day or the session before.
- 8 Jun 2026-8.5%
- 13 Feb 2026-31.6%
Nothing announced by UPB that day or the session before.
Share of unusual movement by asset
For each asset, the share of UPB's own-move activity since 14 Oct 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | TSLP receptorMonoclonal antibody | Chronic Obstructive Pulmonary DiseaseAsthma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (10)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.4M | $37M | $47M+ $160M short-term inv. | $41M-$54M operating cash flow | report ↗ |
View 9 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.8M | $36M | $79M+ $182M short-term inv. | $40M-$36M operating cash flow | report ↗ |
| 2026-Q1 | $1.0M | $37M | $97M+ $198M short-term inv. | $41M-$48M operating cash flow | report ↗ |
| 2025-Q3 | $0.7M | $33M | $72M+ $300M short-term inv. | $34M-$22M operating cash flow | report ↗ |
| 2025-Q2 | $0.9M | $38M | $45M+ $348M short-term inv. | $40M-$39M operating cash flow | report ↗ |
| 2025-Q1 | $0.6M | $26M | $71M+ $360M short-term inv. | $27M-$41M operating cash flow | report ↗ |
| 2024-Q3 | $0.6M | $15M | $33M+ $188M short-term inv. | $16M-$14M operating cash flow | report ↗ |
| 2024-Q2 | $0.5M | $14M | $47M | $15M-$8.0M operating cash flow | report ↗ |
| 2024-Q1 | $0.6M | $12M | $32M | $11M-$18M operating cash flow | report ↗ |
| 2023-Q3 | $0.6M | $7.8M | $47M | $3.1M | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $2.9M | $137M | $102M+ $240M short-term inv. | $36M-$133M operating cash flow | report ↗ |
Upstream Bio reported full-year 2025 revenue of $2.85M, up 20.3% YoY, with R&D spend of $136.81M, up 117.3% YoY. The company posted a net loss of $143.44M for the year and ended the period with cash and cash equivalents of $101.58M.
The company highlighted a Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with plans to initiate Phase 3 dosing in both indications in Q1 2027. Reported business developments include positive top-line results from the Phase 2 VALIANT trial in severe asthma, additional Phase 2 VIBRANT analyses in CRSwNP, and ongoing enrollment in the Phase 2 VENTURE COPD trial, which is more than 60% enrolled. The company also stated that its cash position of $341.5M, including short-term investments, is expected to fund planned operations through 2027.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($105K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-16 | Ambrose Allison · General Counsel | Open-market sale | 485 | $5.49 | $3K | Form 4 |
| 2026-09-16 | Houghton Adam · Chief Business Officer | Open-market sale | 700 | $5.49 | $4K | Form 4 |
| 2026-09-16 | Sutherland Everett Rand · director, Chief Executive Officer | Open-market sale | 2,095 | $5.49 | $12K | Form 4 |
| 2026-09-16 | Deykin Aaron · Chief Medical Officer | Open-market sale | 895 | $5.49 | $5K | Form 4 |
| 2026-09-16 | GRAY MICHAEL · CFO and COO | Open-market sale | 853 | $5.49 | $5K | Form 4 |
| 2026-06-16 | Ambrose Allison · General Counsel | Open-market sale | 477 | $6.10 | $3K | Form 4 |
| 2026-06-16 | Deykin Aaron · Chief Medical Officer | Open-market sale | 895 | $6.10 | $5K | Form 4 |
| 2026-06-16 | Houghton Adam · Chief Business Officer | Open-market sale | 700 | $6.10 | $4K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 140 reporting institutions held 44.9M shares ($403.9M, 81.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 8,101,563 | $72.9M |
| 2 | ORBIMED ADVISORS LLC | 5,693,589 | $51.2M |
| 3 | BlackRock, Inc. | 3,370,689 | $30.3M |
| 4 | Decheng Capital LLC | 2,724,868 | $24.5M |
| 5 | ENAVATE SCIENCES GP, LLC | 2,459,703 | $22.1M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1,873,574 | $16.9M |
| 7 | Y-Intercept (Hong Kong) Ltd | 1,000,631 | $9.0M |
| 8 | FEDERATED HERMES, INC. | 979,758 | $8.8M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 950,617 | $8.6M |
| 10 | MILLENNIUM MANAGEMENT LLC | 937,323 | $8.4M |
| 11 | SEB Asset Management AB | 878,473 | $7.9M |
| 12 | Bain Capital Life Sciences Investors, LLC | 867,211 | $7.8M |
| 13 | Woodline Partners LP | 831,481 | $7.5M |
| 14 | D. E. Shaw & Co., Inc. | 820,480 | $7.4M |
| 15 | Parkman Healthcare Partners LLC | 786,783 | $7.1M |